Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA‐specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients cli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of neurology 2005-11, Vol.12 (11), p.869-878
Hauptverfasser: Weder, C., Baltariu, G. M., Wyler, K. A., Gober, H.-J., Lienert, C., Schluep, M., Radü, E. W., De Libero, G., Kappos, L., Duda, P. W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA‐specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients clinically, by magnetic resonance imaging and by primary immunological assays. Fluctuation of GA‐specific proliferative responses was significantly lower in treatment responders than in untreated patients, and GA‐specific proliferative responses were increased during relapses. These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response.
ISSN:1351-5101
1468-1331
DOI:10.1111/j.1468-1331.2005.01084.x